[
    [
        {
            "time": "",
            "original_text": "康泰生物（300601）：业绩符合预期，下半年将显著恢复【西南医药朱国广陈铁林团队】",
            "features": {
                "keywords": [
                    "康泰生物",
                    "业绩",
                    "下半年",
                    "显著恢复"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物（300601）：业绩符合预期，下半年将显著恢复【西南医药朱国广陈铁林团队】",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业2019年上半年疫苗批签发总结：行业正逐步恢复，核心重磅品种持续放量【西南医药朱国广陈铁林团队】",
            "features": {
                "keywords": [
                    "医药行业",
                    "疫苗",
                    "批签发",
                    "逐步恢复",
                    "核心重磅品种",
                    "持续放量"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2019年上半年疫苗批签发总结：行业正逐步恢复，核心重磅品种持续放量【西南医药朱国广陈铁林团队】",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "8日机构强推买入 六股成摇钱树",
            "features": {
                "keywords": [
                    "机构",
                    "强推买入",
                    "六股",
                    "摇钱树"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "8日机构强推买入 六股成摇钱树",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "康泰生物：在研产品管线丰富 多个重磅产品持续推进",
            "features": {
                "keywords": [
                    "康泰生物",
                    "在研产品",
                    "管线丰富",
                    "重磅产品",
                    "持续推进"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "康泰生物：在研产品管线丰富 多个重磅产品持续推进",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "康泰生物2019年上半年净利2.72亿 比上年同期下降5% 盈利能力下降",
            "features": {
                "keywords": [
                    "康泰生物",
                    "2019年上半年",
                    "净利",
                    "同比下降",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康泰生物2019年上半年净利2.72亿 比上年同期下降5% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]